KR101802675B1 - A herbal mixtuer extract with improved implantation and use thereof - Google Patents

Abstract

More particularly, the present invention relates to a composition for preventing, ameliorating or treating infertility caused by an implantation disorder comprising an ovulation-infested insomniac extract as an effective ingredient.
The ovarian-follicular ovary extract according to the present invention has few side effects and can promote pregnancy by promoting not only ovulation but also fertilization of the fertilized egg. As a result, it is useful for improvement, prevention, suppression or treatment of infertility, It can be used as medicine and health functional food.
In addition, the ovarian-follicular fluid extract of the present invention not only has an antioxidant activity but also exhibits an excellent protective effect against reproductive cytotoxicity caused by VCD which is a representative ovarian toxic substance, and can be used for the improvement, prevention and prevention of premature ovarian failure, Can also be used as medicines and health functional foods useful for inhibition or treatment.

Description

[0001] The present invention relates to an ovulation-enhanced ovary extract having an implantation enhancing effect,

More particularly, the present invention relates to a composition for preventing, ameliorating or treating infertility caused by an implantation disorder comprising an ovulation-infested insomniac extract as an effective ingredient.

With the recent aging society, infertility is increasing as maternal age increases. In addition, due to environmental pollution caused by industrialization and the advancement of women into society, the stress of women is increasing, and the pregnancy rate is significantly lowered. The causes of infertility include genetic defects, environmental defects, and abnormalities in the endocrine system. Male defects are the most common cause of infertility, and sperm and semen defects are the most common causes of infertility. Such as ovulation disorder, transfer of fertilized egg, and implantation disorder.

A variety of infertility and assisted reproductive technologies have been developed to solve these infertility. The most commonly used procedures are intrauterine insemination (IU), in vitro fertilization (embryo transfer) and embryo transfer , IVF-ET, in vitro fertilization). These procedures have different application points, but they are complicated due to complicated procedures, complications caused by superovulation, low pregnancy success rate of about 10-30%, and mental and financial troubles of the family caused by the failure of the procedure . In addition, there is a lot of difficulty in treating infertility caused by implantation disorders with current medical technology. Therefore, development of infertility treatment agent that can increase implantation efficiency is required.

As described above, research on the development of a therapeutic agent capable of treating infertility by promoting implantation efficiency has been a major concern, and research has been conducted (Korean Patent Laid-Open No. 10-2010-0049153) to be.

DISCLOSURE OF THE INVENTION The present invention has been made in order to solve the problems of the prior art as described above. The inventors of the present invention have been studying natural resources having an effect of inducing embryo implantation, And that the effect of promoting implantation of the embryo is excellent, and the present invention has been completed on the basis thereof.

Accordingly, an object of the present invention is to provide a pharmaceutical composition or health functional food composition for preventing, ameliorating or treating infertility due to an implantation disorder, which comprises an ovulation-free ovary extract as an active ingredient.

It is still another object of the present invention to provide a pharmaceutical composition or a health functional food composition for preventing, ameliorating or treating ovarian toxicity and premature ovarian failure, which comprises an ovulation egg extract as an active ingredient.

However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.

In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating infertility caused by an implantation disorder, which comprises an ovulation egg-laying extract as an active ingredient.

In one embodiment of the present invention, the ovulation-stimulated ovariectomized extract may include a tosan, a bokbunja, a ginseng, a ginger, a ginseng, a lobule, a sine, a lobe, a ginkgo, a ginger and a jujube.

10 to 15%: 4 to 9%: 4 to 9%: 10 to 15%: 10 to 20%: 4 to 9% %: 1 to 5%: 4 to 9%: 4 to 9%: 4 to 9%: 20 to 30%: 2 to 7%: 1 to 5%

In addition, the present invention provides a health functional food composition for improving infertility due to an implantation disorder, which comprises an ovulation-free ovary extract as an active ingredient.

Further, the present invention provides a pharmaceutical composition for prevention or treatment of noxious toxicity, which comprises an ovarian-bedded ruminant extract as an active ingredient.

Further, the present invention provides a pharmaceutical composition for preventing or treating premature ovarian failure, which comprises an ovarian egg white extract as an active ingredient.

In addition, the present invention provides a method for preventing or treating infertility or premature ovarian failure due to an implantation disorder, which comprises administering an ovulation-freeze-extract to an individual.

The ovarian-follicular ovary extract according to the present invention has few side effects and can promote pregnancy by promoting not only ovulation but also fertilization of the fertilized egg. As a result, it is useful for improvement, prevention, suppression or treatment of infertility, It can be used as medicine and health functional food.

In addition, the ovarian-follicular fluid extract of the present invention not only has an antioxidant activity but also exhibits an excellent protective effect against reproductive cytotoxicity caused by VCD which is a representative ovarian toxic substance, and can be used for the improvement, prevention and prevention of premature ovarian failure, Can also be used as medicines and health functional foods useful for inhibition or treatment.

FIG. 1 compares the pregnancy success rate results between the normal diet fed group (normal group), the feed group containing the low-density ovulation group, and the feed group containing the high-density ovulation group.
FIG. 2 compares the number of newborns fed with the normal feed group (normal group), the feed group containing the low-density ovulation-fed chamber, and the feed group containing the high-density ovulation-fed chamber.
FIG. 3 is a graph showing the total weight change of a group fed with a normal diet (normal group), a group fed with a diet containing low-density ovulation and a group fed with a diet containing a high-density ovulation diet.
FIG. 4 shows the total feed intake of a group fed with a normal diet (normal group), a group fed with a diet containing a low-density ovulation test, and a group fed a diet containing a high-density ovulation test.
FIG. 5 shows the food efficiency ratio of the group fed with normal diet (normal group), the group fed with low-density ovulation-fed group, and the group fed high-density ovulation-fed diet.
FIG. 6 is a photograph of the uterus extracted to examine embryo implantation in the normal group, the RU486 treated group, and the oocyst-treated high-concentration-intake + RU486-treated group.
FIG. 7 shows the results of counting the number of fetuses in the normal group, the RU486-treated group, and the high-concentration-intake + RU486-treated group.
FIG. 8 shows the results of measurement of DPPH radical and superoxide anion radical scavenging activity of the ovulated egg extract.
FIG. 9 shows the results of measurement of intracellular antioxidant activity of the ovarian-follicle extract by H ₂ DCF-DA method.
FIG. 10 shows the results of confirming the protective effect of the ovulation-induced ovary extract against VCD-induced ovotoxicity.
Fig. 11 shows the result of cytotoxicity of the ovulation-free extract of CHO-K1 cell alone.

The present invention provides a pharmaceutical composition for preventing or treating infertility caused by an implantation disorder, which comprises an ovarian egg white extract as an active ingredient.

In the present invention, the term "ovulation-free ovary extract" means an extract extracted from 11 medicinal materials. The 11 medicinal materials are selected from the group consisting of algae, bokbunja, ginseng, Gugija, Angelica gigas, .

In the composition of the present invention, 10 to 15%: 10 to 20%: 4 to 9%: 4 to 9%: 10 to 15% of the above-mentioned tobacco, bramble, ginseng, , More preferably from 11 to 14%, more preferably from 1 to 5%, from 4 to 9%, from 4 to 9%, from 4 to 9%, from 20 to 30% 5 to 7%: 23 to 28%: 3 to 6%: 2 to 4%: 14 to 18%: 5 to 7%: 5 to 7%: 2 to 4% By weight.

The ovulation-free ovary extract which is an effective ingredient in the composition of the present invention can be obtained by a conventional extraction method, and commercially available ovary extract can be used. Typical extraction methods include, but are not limited to, hot water extraction, cold extraction, reflux extraction, ultrasonic extraction, and the like.

In the present invention, the ovulation-free ovary extract can be obtained by the following method. First, soil, bokbunja, ginseng, Gugija, Angelica gigas, Liliaceae, sinensis, lobster, ganoderma, ginger and jujube are thoroughly washed with water, dried and then mixed and pulverized. The pulverized mixture is subjected to reflux extraction with water, a C ₁ to C ₄ alcohol or a mixed solvent of water and a C ₁ to C ₄ alcohol at 50 to 100 ° C for 1 to 5 hours, preferably for 1 hour and 30 minutes. At this time, the volume of the solvent is 1 to 10 times, preferably 5 to 8 times the weight of the mixed medicinal materials to be pulverized. Thereafter, the extract is filtered, the filtrate is concentrated, and the concentrate is lyophilized to obtain a powdery ovulin-bedded extract.

Implantation is an early pregnancy phenomenon in which blastocysts that are fertilized and developed into embryos are adhered to the endometrial layer of the maternal body. These are normal pregnancies (natural pregnancy), especially those with high success rates in artificial insemination and in vitro procedures The embryo should be smoothly implanted in the endometrium of the mother, which may increase the pregnancy rate. Therefore, the present inventors confirmed the effect of ovulation as well as an ovulation incubation extract promoting the implantation of such embryos.

According to one embodiment of the present invention, when the pregnancy success rate and the number of born lambs of each group were classified by feeding and not feeding the feed containing low concentration / high concentration of ovulation fertilizer, the feed containing the ovulation- (RU486) treated group had a higher embryo implantation rate than the contraceptive (RU486) treated group in feed containing high concentration ovulation incubation group. (See Example 2).

In another embodiment of the present invention, it was confirmed that the antioxidant activity of the ovarian egg extract was superior to DPPH radical and superoxide anion radical scavenging activity and intracellular antioxidant activity. (See Examples 3 to 5).

Therefore, the ovulation-enhanced ovary extract according to the present invention has few side effects and can promote fertilization of the fertilized egg to help maintain pregnancy. As a result, it is possible to provide a medicament useful for the improvement, prevention, suppression or treatment of infertility, And health functional foods.

Furthermore, the ovarian-follicle extract of the present invention not only has an antioxidative effect but also exhibits an excellent protective effect against reproductive cytotoxicity caused by VCD (4-vinylcyclohexene diepoxide), which is a typical ovarian toxic substance, Prevention, suppression, or treatment of diabetes mellitus and the like.

Thus, as another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating ovarian toxicity or premature ovarian failure, which comprises an ovarian egg white extract as an active ingredient.

The pharmaceutical composition of the present invention may contain at least one known active ingredient having an effect of sterilization, neurotoxicity, or early ovarian failure, together with an ovarian stimulated insomnia extract.

The compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions. In addition, it can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, oral preparations such as syrups and aerosols, external preparations, suppositories and sterilized injection solutions according to a conventional method.

Examples of carriers, excipients and diluents that can be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose , Microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When the composition is formulated, it is prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient usually used.

The pharmaceutical composition of the present invention may be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) depending on the intended method, and the dose may vary depending on the condition and the weight of the patient, The mode of administration, the route of administration, and the time, but may be appropriately selected by those skilled in the art.

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dosage level is determined depending on the type of disease, severity, , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including co-administered drugs, and other factors well known in the medical arts. The pharmaceutical composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.

Specifically, the effective amount of the pharmaceutical composition of the present invention may vary depending on the age, sex, condition, body weight, the degree of absorption of the active ingredient in the body, the rate of inactivation and excretion, the type of disease, May be administered in a daily dose of 0.0001 to 150 mg, preferably 0.001 to 100 mg, per 1 kg of body weight or one to three divided doses per day. However, the dosage may be varied depending on the route of administration, the severity of obesity, sex, weight, age, etc. Therefore, the dosage is not limited to the scope of the present invention by any means.

According to still another aspect of the present invention, there is provided a health functional food composition for improving infertility or premature ovarian failure caused by an implantation disorder comprising an ovulation-infested body extract as an active ingredient.

The term "improvement" as used in the present invention means all actions that at least reduce the degree of symptom associated with the condition being treated.

The composition of the present invention may be added to health functional foods for the purpose of preventing or ameliorating infertility or premature ovarian failure due to implantation disorders. When the ovarian egg white extract of the present invention is used as a food additive, the ovarian egg white extract can be directly added or used together with other food or food ingredients, and can be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). Generally, the ovulation-free oozing extract of the present invention is added in an amount of not more than 15% by weight, preferably not more than 10% by weight based on the raw material. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.

There is no particular limitation on the kind of the food. Examples of the food to which the above substances can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include health functional foods in a conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The above-mentioned natural carbohydrates are monosaccharides such as glucose and fructose, polysaccharides such as disaccharides such as maltose and sucrose, dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.20 g, preferably about 0.04 to 0.10 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, A carbonating agent used in a carbonated beverage, and the like. In addition, the composition of the present invention may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the ratio of such additives is not critical, it is generally selected in the range of 0.01 to 0.20 parts by weight per 100 parts by weight of the composition of the present invention.

Further, as another embodiment of the present invention, the present invention provides a method for preventing or treating infertility, premature ovarian failure, or pre-menopausal menopausal disorder due to an implantation disorder, which comprises administering an ovulation- The subject is a mammal including a human or non-human, and non-human mammals include, but are not limited to, mice, rats, dogs, cats, horses, cows, sheep, goats, pigs, rabbits and the like.

Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the following examples.

[Example]

Example  One. Ovulation conception room  Extract preparation

4: 4: 4: 4: 4: 4: 4: 4: 16: 3: 2 ratio of ginseng: ginseng: ginseng: jujube The convalescent room (240 g) was soaked with 1 L of tertiary distilled water for 1 hour and 30 minutes, and the extract was subjected to centrifugation and filtration, frozen at -80 ° C, and freeze-dried. The lyophilized medicinal materials were weighed and stored at -80 ° C.

Example  2. Ovulation conception room  Verification of efficacy of infertility treatment according to promotion of extract

2-1. Identification of therapeutic efficacy in animal model by ovulation-stimulated cocoon extract

In order to confirm whether the ovarian egg extract prepared in Example 1 was effective for the infertility treatment by implantation, male Balb / c and female Balb / c, which were 5 weeks old and 4 weeks old, were purchased and used for the experiment after one week of adaptation. Assuming that the amount of feed consumed per mouse was 5 g per day, the intakes of the ovulation follicles were 100 mg / kg (low concentration) and 300 mg / kg (high concentration). The experimental group was fed with diets containing normal ovum (normal group), diets containing low density ovulation room (ovulation temperature: 100 mg / kg / day), diets containing high concentration ovulation room : 300 mg / kg / day). Each group consisted of 4 males and 8 females. Each group was fed with a diet containing the drug for one week. One male and one male Two womens were mated for 5 days and the vaginal plug was considered as the first day of pregnancy. After this, the pregnancy success rate and the number of births were compared.

As a result, as shown in FIG. 1 and FIG. 2, in the normal group, low concentration and high concentration of ovulation fertilization, six out of eight pregnancies had a pregnancy / delivery rate of 75.0%. In the normal group, 23 birds were born in 6 mothers and 3.83 breeds were born on average. A total of 23 mothers of 6 oocytes obtained the oocyst injection low concentration (100 mg / kg) As in the normal group, 3.83 breeds were born in the same way as the normal group. However, in the group that ingested high concentration of ovulation follicles (300 mg / kg), a total of 37 breeds were born in 6 mothers and an average of 6.17 breeds were born (P <0.05), respectively.

2-2. Evaluation of body weight, feed intake and feed intake efficiency

The total weight change, total feed intake, and feed intake efficiency of the normal group and ovulation - free group were evaluated during the 35 - day experimental period.

As a result, as shown in FIG. 3 to FIG. 5, there was no significant difference in the total weight change, feed intake and feed intake efficiency between the normal group and the ovulation-free group.

From the above results, it can be confirmed that the ingestion of the ovariectomized ruminant extract according to the present invention does not affect the dietary efficiency in the animal model.

2-3. Identification of the therapeutic efficacy in the failure model of embryo implantation according to the ovulation-fuga extract

5-week old male and 4-week old female Balb / c (male rats) were used in the same manner as in Example 2-2 to confirm whether or not the ovulation- Were purchased and used for the experiment after one week of adaptation. The rats were fed a diet containing 0.08 mg / 0.1 ml of RU486 subcutaneously (RU486-treated group) and a high-density ovulation-fed diet on the fourth day of pregnancy. The rats were divided into subcutaneous injections of 0.08 mg / 0.1 ml of RU486 (high-concentration ovulation + RU486 treatment) and one 6-week-old male and two 5-week old female cages per cage. And when the vaginal plug was seen, it was considered as the first day of pregnancy. The RU486 treated group and the ovulatory follicular fluid + RU486 treated group underwent subcutaneous injection of RU486 on the fourth day of pregnancy and the number of implanted embryos was examined one week after the RU486 injection.

As a result, as shown in FIG. 6 and FIG. 7, in the normal group, a total of 20 embryos were implanted in 3 mother and an average of 6.67 embryos were implanted, whereas in the group treated with RU486, A total of 5 embryos were implanted and an average of 1 embryo was implanted, indicating a significant decrease (p <0.01). However, it was confirmed that a total of 19 embryos were implanted in 6 mothers in the high-concentration oviposition / RU486-treated group, and an average of 3.17 embryos were implanted, thus showing no significant difference from the normal group p = 0172).

From the above results, the number of embryos implanted was lower than that of the normal group, but RU486 was higher in the group treated with ovulation + RU486 than in the group treated with ovulation. It was confirmed that the embryo implantation could further induce embryo implantation in rats after the contraceptive (RU 486) treatment.

Example  3. Ovulation conception room  Antioxidant efficacy of extract

DPPH radical scavenging activity was measured in order to confirm antioxidative effect of ovulated egg extract. More specifically, 1 ml of a 1 M DPPH solution and 450 쨉 l of 50 mM Tris-HCl buffer (pH 7.4) were added to 50 쨉 l of the ovarian-follicular extract, followed by mixing. The mixture was reacted at room temperature for 30 minutes and absorbance was measured at 517 nm using a microplate reader (VersaMax, Molecular Devices, USA).

In addition, the scavenging activity for the peroxide anion, which is one of representative reactive oxygen species as another index of the antioxidant activity, was measured by the NBT reduction method. More specifically, 10 μl of 30 mM EDTA (pH 7.4), 1 μl of 30 mM hypoxanthine and 200 μl of 1.42 mM NBT were added to 30 μl of the sample, followed by reaction at room temperature for 3 minutes, followed by addition of 10 μl of 1 U / ml xanthine oxidase And the total volume was adjusted to 300 μl with 50 mM phosphate buffer (pH 7.4). The reaction solution was incubated at room temperature for 20 minutes, and the absorbance at 560 nm was measured.

As a result, as shown in Fig. 8, it was confirmed that the ovarian egg-laying extract had an excellent antioxidative effect, and in particular, the higher the concentration, the better the antioxidative effect.

Example  4. CHO -K1 cells H ₂ O ₂ in  Induced To ROS  About Ovulation  Efficacy verification

Ovulation, implantation room H ₂ a ROS (reactive oxygen species) in the CHO-K1 cells from oxidative stress state induced with O ₂ in order to determine the effect of generating, H ₂ DCF-DA Experiment number ovulation implanted cells using my Antioxidant .

As a result, as shown in Fig. 9, it was confirmed that the ovary-seeded embryo extract showed excellent intracellular antioxidant ability.

Example 5: Covalent protective effect of ovulation-induced oocyte extract on ovotoxicity induced by VCD in CHO-K1 cells

Cell viability was evaluated by 3- (4,5-dimethylthiazol) -2,5-diphenyltetrazolium bromide (MTT) assay method in order to confirm the cytoprotective effect of ovulation-free extract of the present invention.

More specifically, CHO-K1 cells were cultured in a 96-well plate at a concentration of 1 × 10 4 cells / well. After serum starvation for 4 hours, the ovulation incubation room was pre-treated with 100 μg / ) Were sequentially treated and cultured at 37 ° C and 5% CO ₂ for 24 hours. Then, 10 μl of MTT solution (2 mg / ml) was added to each well, and incubated at 37 ° C in a 5% CO ₂ incubator for 3 hours. After the MTT solution and the culture solution were completely removed, 100 μl of dimethyl sulfoxide DMSO, Sigma-Aldrich, USA), and the absorbance at 595 nm was measured with an ELISA plate reader (DYNEX, Opsys MR, USA). At this time, the cell survival rate of the control group was expressed as a percentage. In addition, the cytotoxicity of the ovariectomized rumen extract alone was evaluated by MTT assay.

As a result, as shown in Fig. 10 and Fig. 11, it was confirmed that the ovulation-free extract of the ovary was superior in cytoprotective effect from VCD-induced cytotoxicity, and up to 500 ㎍ / It was confirmed that there was no cytotoxicity since it did not affect cell survival rate.

It will be understood by those skilled in the art that the foregoing description of the present invention is for illustrative purposes only and that those of ordinary skill in the art can readily understand that various changes and modifications may be made without departing from the spirit or essential characteristics of the present invention. will be. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive.

Claims (6)

Wherein the ovulation incubation room extract comprises an ovulation incubation room extract as an active ingredient and the ovulation incubation room extract comprises a tosser, a bokbunja, a ginseng, a gingiva, a ginseng, a lobule, a sign, a lobe, &Lt; / RTI &gt; or a pharmaceutically acceptable salt thereof.
delete The method according to claim 1, wherein 10 to 15%: 10 to 20%: 4 to 9%: 4 to 9% of the algae, bramble, ginseng, The pharmaceutical composition according to claim 1, wherein the composition is formulated in a weight ratio of 1 to 5%: 4 to 9%: 4 to 9%: 4 to 9%: 20 to 30%: 2 to 7%: 1 to 5%
Wherein the ovulation incubation room extract comprises an ovulation incubation room extract as an active ingredient and the ovulation incubation room extract comprises a tosser, a bokbunja, a ginseng, a gingiva, a ginseng, a lobule, a sign, a lobe, A functional food composition for improving infertility caused by.
A method for preventing noxious toxicity, comprising the step of administering an ovulation-preventing cow extract as an active ingredient, wherein the ovulation-cow cow-house extract comprises tobacco, bokbunja, ginseng, goji, angelica, Or a pharmaceutically acceptable salt thereof.
An ovarian follicle extract comprising an ovarian follicle extract as an active ingredient and the ovulation follicle extract comprises an extract of a follicular ovary, a ginseng, a ginseng, a ginseng, a calyx, a lobule, a lobster, A pharmaceutical composition for preventing or treating.

Images